Full Press Release Details
| Press Release | Media contact |
| Christine Peters | |
| T +49 160 60 66 770 | |
| christine.peters@freseniusmedicalcare.com | |
| Contact for analysts and investors | |
| Dr. Dominik Heger | |
| T +49 6172 609 2601 | |
| dominik.heger@freseniusmedicalcare.com | |
| www.freseniusmedicalcare.com |
Fresenius Medical Care appoints Joseph Turk as new Management Board
Member for Care Enablement
| Effective January 1, 2026, Joseph Turk will join the Management Board as Chief Executive Officer of the global operating segment Care Enablement | ||
| As part of a planned transition Dr. Katarzyna Mazur-Hofs will retire by year end |
Bad Homburg (October 1, 2025) - The Supervisory Board
of Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal disease, has appointed
Joseph E. (Joe) Turk (57) as a member of the Management Board, effective January 1, 2026. Mr. Turk will serve as Chief Executive
Officer of the global operating segment Care Enablement.
Mr. Turk will succeed Dr. Katarzyna Mazur-Hofs
(62) as part of a planned transition after she informed the Supervisory Board of her intention to retire. Dr. Mazur-Hofs
joined Fresenius Medical Care in 2018 and has been leading Care Enablement since its creation in 2022.
Mr. Turk joined Fresenius Medical Care in 2019, following the
acquisition of NxStage Medical. He currently serves as Executive Vice President of Global Home and Critical Care Therapies as well as
Head of US Commercial Operations. Before joining, he held positions at Boston Scientific, McKinsey & Company and Deloitte and
holds a master's in marketing, finance and operations from the J.L. Kellogg Graduate School of Management, Northwestern University
(Illinois, U.S.), and a degree in economics and chemistry from Wabash College (Indiana, U.S.).
Michael Sen, Chairman of the Supervisory Board of Fresenius Medical
"We are delighted to have Joe Turk join the Management Board
of Fresenius Medical Care. With his expertise and commitment, he will be instrumental in continuing the margin improvement track of Care
Enablement, successfully rolling out the innovative 5008X CAREsystem to the U.S. and advancing innovation in the space. It is great to
have such an experienced and capable successor from within the organization." Michael Sen added: "On behalf of the entire
Supervisory Board, I would like to express my sincere appreciation to Katarzyna for her excellent work and her commitment over the
past years. We wish her all the best for her retirement."
Helen Giza, CEO and Chair of the Management Board, said: "Joe
joins the Fresenius Medical Care Management Board as a well-known colleague with a strong proven track record. He will be a valuable member
of my leadership team and ensure uninterrupted execution of our FME Reignite strategy in this important phase for Care Enablement. I would
like to thank Katarzyna for her significant contribution to fundamentally transforming and reshaping Care Enablement. I wish her well
Joe Turk said: "I am excited to join the Fresenius Medical Care
Management Board at a time when it has embarked on the FME Reignite strategy, where Care Enablement will play a crucial role in innovating
for patients, caregivers and customers. I look forward to continuing working with all committed employees worldwide."
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading
provider of products and services for individuals with renal diseases of which around 4.2 million patients worldwide regularly undergo
dialysis treatment. Through its network of 3,676 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 300,000
patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers.
Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the Company's website at www.freseniusmedicalcare.com.
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially
from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic
and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties
in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in
Fresenius Medical Care's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake
any responsibility to update the forward-looking statements in this release.